<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005053</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16994P</org_study_id>
    <secondary_id>EORTC-16994P</secondary_id>
    <secondary_id>ASTA-D-19575-3166</secondary_id>
    <nct_id>NCT00005053</nct_id>
  </id_info>
  <brief_title>Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer</brief_title>
  <official_title>Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Hydration with a saline solution may protect kidney cells from the
      side effects of chemotherapy.

      PURPOSE: Randomized phase II trial to compare the effectiveness of glufosfamide with or
      without hydration in treating patients who have pancreatic cancer that is metastatic or
      cannot be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the activity of glufosfamide as determined by objective response in
      patients with metastatic or inoperable locally advanced pancreatic cancer. II. Determine the
      response rate in this patient population after this treatment. III. Determine the duration of
      objective response in these patients on this treatment. IV. Determine the toxic effects of
      this regimen in these patients. V. Assess the impact of hydration on the toxicity profile of
      this treatment in these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two
      treatment arms: Arm I: Patients receive glufosfamide IV over 1 hour on day 1. Arm II:
      Patients receive glufosfamide as in arm I. Patients are hydrated with excess physiological
      saline solution 4 hours before and for 3 hours after treatment with glufosfamide. Treatment
      repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
      Patients with an objective complete response continue treatment for a maximum of 2 courses
      beyond confirmation of response. Patients are followed every 6 weeks until disease
      progression.

      PROJECTED ACCRUAL: A total of 16-32 patients (8-16 per arm) will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <primary_completion_date type="Actual">March 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">35</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glufosfamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven metastatic or inoperable locally advanced
        pancreatic adenocarcinoma At least 1 target lesion accurately measurable in at least 1
        dimension Longest diameter at least 20 mm with conventional techniques or at least 10 mm
        with spiral CT scan No symptomatic brain metastases

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
        least 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count
        at least 100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN)
        Alkaline phosphatase and transaminases no greater than 2.5 times ULN (no greater than 5
        times ULN for liver metastases) Renal: Creatinine no greater than 1.7 mg/dL Creatinine
        clearance at least 60 mL/min Cardiovascular: Normal cardiac function No history of ischemic
        heart disease No history of congestive heart failure within the past 6 months Normal 12
        lead electrocardiogram Other: Not pregnant or nursing Negative pregnancy test Fertile
        patients must use effective contraception No other prior or concurrent malignancy, except:
        Cone biopsied carcinoma of the cervix Adequately treated basal or squamous cell skin cancer
        No unstable systemic disease No active uncontrolled infection No psychological, familial,
        sociological, or geographical condition that would preclude study compliance

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent prophylactic filgrastim (G-CSF)
        No concurrent prophylactic growth factors Chemotherapy: No prior chemotherapy for
        metastatic or advanced disease Endocrine therapy: Not specified Radiotherapy: At least 4
        weeks since prior radiotherapy Concurrent radiotherapy allowed provided not all target
        lesions are in irradiated field Surgery: At least 2 weeks since prior major surgery Other:
        No other concurrent anticancer agents No other concurrent investigational therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas A. Pavlidis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Ioannina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital - University Hospital of Copenhagen</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats-Krankenhaus Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemato-Onkologische Praxis und Tagesklinik</name>
      <address>
        <city>Munich</city>
        <zip>D-80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nurnberg</name>
      <address>
        <city>Nuremberg</city>
        <zip>D-90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>GR-45110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis der Vrije Universiteit</name>
      <address>
        <city>Amsterdam</city>
        <zip>1117 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - Saint Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Briasoulis E, Pavlidis N, Terret C, Bauer J, Fiedler W, Sch√∂ffski P, Raoul JL, Hess D, Selvais R, Lacombe D, Bachmann P, Fumoleau P. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer. 2003 Nov;39(16):2334-40.</citation>
    <PMID>14556925</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>April 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2004</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

